On January 9, 2023 Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, reported that its licensee, Surface Oncology (NASDAQ: SURF, "Surface") dosed the first patient in its Phase 1/2 clinical study investigating SRF114, an antibody discovered using Vaccinex’s ActivMAb antibody discovery platform and licensed to Surface Oncology in 2021 (Press release, Vaccinex, JAN 9, 2023, View Source [SID1234626116]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very pleased that Surface has progressed SRF114 into a Phase 1/2 clinical study. Advancing this promising drug candidate into the clinic provides positive validation of our proprietary ActivMAb antibody discovery platform," said Ernest Smith, PhD, Chief Scientific Officer of Vaccinex. "ActivMAb is particularly focused on antibody targets like CCR8, a complex GPCR protein. We are gratified that we were able to provide Surface Oncology with a potential best-in-class anti-CCR8 antibody and look forward to continued progress for the SRF114 program."
SRF114 is a potential best-in-class, fully human monoclonal antibody targeting, CCR8. SRF114 was designed to selectively deplete immuno-suppressive tumor T regulatory cells (Tregs) while sparing peripheral Tregs. The highly specific binding properties of the antibody are believed to position SRF114 as a potential best-in-class anti-CCR8 antibody as a monotherapy for the treatment of advanced solid tumors. Under the terms of the antibody discovery agreement, Vaccinex has the potential to receive progress-related clinical milestone payments and royalties on sales.